Plenary lecture 2: Dynamics of HCV envelope glycoproteins and the link with immune evasion
Jannick Prentoe, University of Copenhagen, Denmark

Plenary lecture 3: Structural biology of flavivirus envelope proteins and antibody neutralization
Shee-Mei Lok, Duke - NUS Medical School, Singapore

Oral presentations selected from abstract submission

---

The role of the phosphatidylserine receptor TIM1 in the entry of the hepatitis E virus
Laura Corneillie, Ghent University, Belgium

---

ACE2 is a mutual entry factor for HCV and SARS-CoV-2
Meital Gal Tanamy, Bar-Ilan University, Israel

---

Post-translational modifications of flaviviral proteins modulate entry and RNA replication
Zachary Walter, Thomas Jefferson University, USA

Pitch your poster presentations

---

Identification of SLC35F5 as a Hepatitis E Virus Entry Factor Candidate based on Protein Microarray Analyses
Volker Kinast, Carl von Ossietzky University Oldenburg and Ruhr-University Bochum, Germany

---

The role of complement regulatory protein CD46 as molecular determinant in pestiviral entry
Alexander Postel, University of Veterinary Medicine Hannover, Germany

Plenary lecture 4: A molecular scar in exhausted virus-specific CD8+ T cells hinders functional memory formation after HCV cure
Maike Hofmann, University of Freiburg, Germany

Oral presentations selected from abstract submission

---

Restored hepatitis C virus-specific CD4+ T cells associated with viral control after childbirth express cytokine, transcription factor, and chemokine receptor signatures of a Th1-biased Tfh lineage
Christopher Phelps, Nationwide Children's Hospital, USA

---

Convergent co-evolution of multiple human HCV bNAb lineages with diverse VH-genes
Clinton O. Ogega, Johns Hopkins University School of Medicine, USA

---

Structural studies of flavivirus-antibody complexes and comparison with hepatitis C virus
Richard J. Kuhn, Purdue University, USA

Pitch your poster presentations

---

Broadly neutralizing human monoclonal antibodies targeting the Hepatitis E virus ORF2 protein
George Ssebyatika, University of Lübeck, Germany

---

Contribution of HEV soluble ORF2 protein to viral replication and host immune response
Philipp Ralfs, Emory University, USA

---

Distinct B cell receptor repertoire signatures distinguish spontaneous clearance of hepatitis C virus and development of broadly neutralizing antibodies
Nicole Skinner, Nationwide Children's Hospital, USA

---

A Zika virus-specific IgM elicited during pregnancy exhibits isotype-dependent ultrapotent neutralization.
Mattia Bonsignori, Duke University School of Medicine and NIAID, NIH, USA

---

Antibody neutralization and potential effector functions directly after primary HCV is associated with the protection against reinfection
Ana Chumbe, University of Amsterdam, The Netherlands

Pitch your poster presentations

---

Single-cell level analysis of the cell-intrinsic antiviral response to hepatitis E virus infection in induced pluripotent stem cell-derived hepatocytes
Ann-Kathrin Mehnert, University Hospital Heidelberg, Germany

---

A novel zebrafish-based in vivo model of Zika virus infection unveils NS4A as a key viral determinant of neuropathogenesis
Laurent Chatel-Chaix, Institut National de la Recherche scientifique, Canada

---

Interplay between hepatitis C virus and peroxisomes.
Esther Martin de Fourchambault, Institut Pasteur de Lille and Université de Lille, France

---

Chronic HCV Infection Fuels HIV Reservoir Persistence in CD4-T Cells: Beneficial Effects of Direct Acting Antivirals
Samaa T. Gobran, Université de Montréal, Canada

---

Impact of physiologically prolonged hypoxia on Zika virus infection and consequences on cellular disturbance
Marianne Maquart, Université de Tours, France

---

Hepatitis C Virus Genotype 1a Transmission Dynamics in the UK Population
John McLauchlan, MRC-University of Glasgow, UK

---

Investigating Phylogenetic Dynamics of Hepatitis C Virus Genotype 3a in the UK Population
John McLauchlan, MRC-University of Glasgow, UK

---

MS-TRACE: molecular surveillance of transmission networks for hepatitis C elimination in men who have sex with men
Jelle Koopsen, University of Amsterdam, The Netherlands

---

Hepatitis C virus transmission dynamics in a global cohort of men who have sex with men with recently acquired infections
Jelle Koopsen, University of Amsterdam, The Netherlands

---

An 8-gene machine learning model improves clinical prediction of severe dengue progression
Sirle Saul, Stanford University, USA

---

NS5A domain I Antagonises PKR to facilitate the assembly of infectious hepatitis C vrisu particles
Mark Harris, University of Leeds, UK

Plenary lecture 5: In silico, in vitro and in vivo models to study vaccine efficacy
Thomas Pietschmann, Twincore, Hannover, Germany

Plenary lecture 6: An epitope-focused hepatitis C virus vaccine - a perspective
Thomas Krey, University of Lübeck, Germany

Plenary lecture 7: Are T cells still relevant in the age of neutralizing antibodies?
Naglaa Shoukry, Université de Montréal, Canada

Plenary lecture 8: Pathways for vaccine development for hepatitis C
Heidi Drummer, Burnett Institute, Melbourne, Australia

Plenary lecture 9: Preparing a vaccine for the next pandemic - lessons learnt from COVID-19
Tess Lambe, Oxford University, UK

Oral presentations selected from abstract submission

---

Investigating factors that limited immunogenicity in vectored hepatitis C virus vaccine trial
Kimberly E. Rousseau, Johns Hopkins University School of Medicine, USA

---

Vesicular stomatitis virus (rVSV) vectored HCV vaccine candidate induces potent cross-neutralizing antibodies
Maurice Labuhn, Twincore Center of Experimental and Clinical Infection Research, Germany

---

Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection
Ji Ma, Rega Institute - KULeuven, Belgium

---

Robust CD8+ and CD4+ T cell responses with an HCV vaccine adjuvanted with TLR4 agonists
Abdolamir Landi, University of Alberta, Canada

Oral presentations selected from abstract submission

---

Structure of the hepatitis C virus E1E2 glycoprotein complex
Kwinten Sliepen, University of Amsterdam, The Netherlands

---

Structural analysis of a native-like secreted form of the HCV E1E2 glycoprotein and immunological analysis in mice and macaques
Thomas Fuerst, University of Maryland, USA

---

Inactivated genotype 1a, 2a or 3a HCV vaccine candidates induced broadly neutralizing antibodies in mice
Garazi Pena Alzua, University of Copenhagen, Denmark

---

Repeated exposure to heterologous, antibody sensitive hepatitis C viruses is associated with induction of potent and broadly neutralizing antibodies
Nicole Frumento, Johns Hopkins University School of Medicine, USA

Pitch your poster presentations

---

Molecular determinants of mouse adaptation of rat hepacivirus
Raphael Wolfisberg, University of Copenhagen, Denmark

---

Virus-like-particle immunizations elicit cross-reactive antibody responses which recognize divergent pathogenic flaviviruses and promote both neutralization and infection enhancement
Richard Brown, Paul-Ehrlich-Institute, Germany

---

Adaptation of Hepatitis C virus for the generation of a HCV mouse model
Julie Sheldon, Twincore Center of Experimental and Clinical Infection Research, Germany

---

Broad Immunogenicity of a Nucleoside-modified mRNA Lipid Nanoparticle Vaccine for Hepatitis C Virus Prophylaxis
Erin K. Reagan, University of Pennsylvania , USA

---

The development of a pan-genotypic viral vectored T cell vaccine against hepatitis C
Rebecca Strain, University of Oxford, UK

Plenary lecture 10: Leveraging the design of mRNA vaccines to increase their succes in a prophylactic setting
Leonie Wyffels, Ziphius Vaccines, Belgium

Plenary lecture 11: The case for and against adjuvanted HCV protein vaccines
Michael Houghton, University of Alberta, Canada

Plenary lecture 12: Controlled human infection studies for the development of HCV vaccines
Jake Liang, NIH, NIDDK, USA

Plenary lecture 13: Drug development for flaviviruses
Johan Neyts, Rega Institute - KULeuven, Belgium

Plenary lecture 14: HCV elimination
Heiner Wedemeyer, Hannover Medical School, Germany

Oral presentations selected from abstract submission

---

Virological characterization of treatment failures and retreatment outcomes in patients infected with “unusual” HCV genotype 1 subtypes
Slim Fourati, Hôpital Henri Mondor, Université Paris-Est, France

---

Targeting the capsid protein – a strategy for the generation of a broadly acting Flaviviridae inhibitor
Natalia Ruetalo, University Hospital Tübingen, Germany

---

Novel indolediketopiperazine derivatives targeting the replication of Flaviviridae viruses
George Mpekoulis, Hellenic Pasteur Institute, Greece

Pitch your poster presentations

---

Screening of the antiviral activity of existing drugs against tick-borne encephalitis and yellow fever viruses in human cell lines
Alekxander Binderup, University of Copenhagen, Denmark

---

Dengue virus infection and dissemination in Aedes aegypti mosquitoes is significantly reduced upon exposure to JNJ-A07, a potent DENV inhibitor, in the blood meal
Leen Delang, Rega Institute - KULeuven, Belgium

Oral presentations selected from abstract submission

---

Recapitulating hepatitis E virus-host interactions in human liver and intestinal organoids
Pengfei Li, Erasmus MC-University Medical Center, The Netherlands

---

Resistance to NS5A-inhibitors and enhanced viral fitness compromise the efficacy of pangenotypic antiviral regimens against hepatitis C virus genotype 3 in cell culture
Carlota Fernandez Antúnez, University of Copenhagen, Denmark

Plenary lecture 15: Host-factors involved in flavivirus infection
Hans-Heinrich Hoffmann, Rockefeller University, USA

Oral presentations selected from abstract submission

---

Hepatitis C virus RNA is 5’ capped with flavin adenine dinucleotide
Jeppe Vinther, University of Copenhagen, Denmark

---

A pan-Flavivirus capsid interactome ATLAS identifies novel sub- and pan-flaviviral activities
Pietro Scaturro, Leibniz Institute for Experimental Virology, Germany

---

A Hepatitis C virus genotype 1b isolate with high replication efficiency in cell culture and its adaptation to infectious virus production in vitro and in vivo
Paul Rothhaar, Heidelberg University, Germany

Hepatitis E virus replication is controlled by a novel mechanism of polyprotein processing
Morgan Herod, University of Leeds, UK

---

Interdomain interaction stabilized by divalent cation coordination within hepatitis E virus open reading frame 1 protein provides structural features critical for viral replication
Robert LeDesma, Princeton University, USA

---

CRISPR activating the genome to identify novel anti-viral restriction factors of flavivirus replication
Michael R. Beard, University of Adelaide, Australia

Plenary lecture 16: Lipid droplets grease viral replication: role in assembly and beyond
Gabriëlle Vieyres, Leibniz Institute for Experimental Virology, Germany

Plenary lecture 17: Cellular regulation of HCV release
Jin Zhong, Chinese Academy of Sciences, Institut Pasteur of Shanghai, China

Oral presentations selected from abstract submission

---

The cargo adaptor protein CLINT1 is phosphorylated by the Numb-associated kinase BIKE and mediates dengue virus infection
Sirle Saul, Stanford University, USA

---

Core protein promotes clustering and intracellular redistribution, but not biogenesis of lipid droplets during HCV infection
Angeliki-Anna Beka, Institut Pasteur, France

Pitch your poster presentations

---

Viral determinants of hepatitis C virus cell culture adaptation and their relevance for enhanced replication fitness
Nicola Frericks, Twincore Center of Experimental and Clinical Infection Research, Germany

---

Dynamic hepatitis E virus genomic rearrangements observed in vivo as determinants for viral fitness, resistance and immune escape
Daniel Todt, Ruhr University Bochum, Germany

---

Pestivirus dependency on micro-RNA-17 is controlled by the host cell
Rui Costa, University of Copenhagen, Denmark

Plenary lecture 19: Immune modulation of Abs via FcR signaling
Taia Wang, Stanford University, USA

Oral presentations selected from abstract submission

---

An atlas of the human liver circadian transcriptome and its carcinogenic perturbation by hepatitis C virus infection.
Atish Mukherji, Université de Strasbourg, France

---

Cellular and molecular determinants preceding the progression to severe dengue in children and adults via virus-inclusive single cell RNAseq approach
Luca Ghita, Stanford University School of Medicine, USA

---

The magnitude and kinetics of immune responses associated with severe dengue progression in humans via proteomic single-cell profiling of PBMCs
Makeda L. Robinson, Stanford University School of Medicine, USA

---

IL-15-induced activation of liver damaging bystander T cells is insensitive to PD-1-mediated inhibition in viral hepatitis.
Hoyoung Lee, Korea Virus Research Institute, Republic of Korea

Plenary lecture 18: Human anti-dengue antibody responses
Tineke Cantaert, Institut Pasteur de Cambodja, Cambodja

Oral presentations selected from abstract submission

---

Is contemporary Zika getting more on your nerves?
Maïlis Darmuzey, KU Leuven and Université de Liège, Belgium

---

Impact of HCV genotypic variability on hepatocyte pathway deregulations in link with steatosis and HCC
Angeliki-Anna Beka, Institut Pasteur, France

---

Contribution of the Cellular Lipid Kinase PI4KA to HCV-induced Liver Pathogenesis
Cong Si Tran, University of Heidelberg, Germany

Plenary lecture 20: Innate immune responses to flaviviruses
Sonja Best, NIH, NIAID, USA

Oral presentations selected from abstract submission

---

Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation.
Ombretta Colasanti, University of Heidelberg, Germany

---

An interactome study identifies a novel antiviral factor in Flavivirus infection
Andrew Isopi, Thomas Jefferson University, USA

---

Proteomics approaches identify post-translational modifications that regulate Flavivirus infection
Holly Ramage, Thomas Jefferson University, USA

Presentation of HCV-Flavi 2023 meeting

Closing remarks